Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Rybak

Showing results (41-50 of 137) with videos related to

Pageof 14
Sort By:
Antimicrobial Agents and Chemotherapy|May 1, 1996
Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and -resistant Streptococcus pneumoniae in an in vitro pharmacodynamic infection modelD M Cappelletty, M J Rybak
Expert Opinion on Emerging Drugs|July 2, 2005
Oxazolidinones: new players in the battle against multi-resistant Gram-positive bacteriaG W Kaatz, M J Rybak
Drug Intelligence & Clinical Pharmacy|September 1, 1982
Antimicrobial susceptibility testsS A Hunt, M J Rybak
Clinical Pharmacy|November 1, 1984
Antihypertensive agents and hyperlipidemiaL M Gutschi, M J Rybak
Antimicrobial Agents and Chemotherapy|April 19, 2000
Activities of trovafloxacin and ampicillin-sulbactam alone or in combination versus three strains of vancomycin- intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection modelJ R Aeschlimann, E Hershberger, M J Rybak
The Annals of Pharmacotherapy|January 1, 1992
Intravitreal ganciclovir for cytomegalovirus retinitis in AIDS patientsW R Melchior, V Bindlish, M J Rybak
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|December 1, 1996
Stability and antimicrobial activity of gentamicin sulfate, tobramycin sulfate and amikacin sulfate in polypropylene syringes for use in once-daily aminoglycoside therapyB Mitrzyk, P E Jarco, M J Rybak
Antimicrobial Agents and Chemotherapy|August 3, 1999
Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcus aureusJ R Aeschlimann, E Hershberger, M J Rybak
DICP : the Annals of Pharmacotherapy|May 1, 1990
CefiximeN J Leggett, C Caravaggio, M J Rybak
Pharmacotherapy|February 24, 2001
Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactamT K Jellison, P S Mckinnon, M J Rybak
Pageof 14

Showing results (41-50 of 137) with videos related to

Sort By:
Pageof 14
Antimicrobial Agents and Chemotherapy|May 1, 1996
Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and -resistant Streptococcus pneumoniae in an in vitro pharmacodynamic infection modelD M Cappelletty, M J Rybak
Expert Opinion on Emerging Drugs|July 2, 2005
Oxazolidinones: new players in the battle against multi-resistant Gram-positive bacteriaG W Kaatz, M J Rybak
Drug Intelligence & Clinical Pharmacy|September 1, 1982
Antimicrobial susceptibility testsS A Hunt, M J Rybak
Clinical Pharmacy|November 1, 1984
Antihypertensive agents and hyperlipidemiaL M Gutschi, M J Rybak
Antimicrobial Agents and Chemotherapy|April 19, 2000
Activities of trovafloxacin and ampicillin-sulbactam alone or in combination versus three strains of vancomycin- intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection modelJ R Aeschlimann, E Hershberger, M J Rybak
The Annals of Pharmacotherapy|January 1, 1992
Intravitreal ganciclovir for cytomegalovirus retinitis in AIDS patientsW R Melchior, V Bindlish, M J Rybak
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|December 1, 1996
Stability and antimicrobial activity of gentamicin sulfate, tobramycin sulfate and amikacin sulfate in polypropylene syringes for use in once-daily aminoglycoside therapyB Mitrzyk, P E Jarco, M J Rybak
Antimicrobial Agents and Chemotherapy|August 3, 1999
Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcus aureusJ R Aeschlimann, E Hershberger, M J Rybak
DICP : the Annals of Pharmacotherapy|May 1, 1990
CefiximeN J Leggett, C Caravaggio, M J Rybak
Pharmacotherapy|February 24, 2001
Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactamT K Jellison, P S Mckinnon, M J Rybak
Pageof 14